End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.66 MXN | -1.88% | +2.21% | +17.66% |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 13.14 for the current year.
- The company has a low valuation given the cash flows generated by its activity.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.66% | 910M | B+ | ||
+21.85% | 546B | B | ||
-4.77% | 359B | C+ | ||
+16.97% | 323B | B- | ||
+5.69% | 290B | C+ | ||
+13.68% | 234B | B+ | ||
+3.65% | 198B | B- | ||
-11.12% | 194B | A+ | ||
+8.08% | 167B | C+ | ||
-3.40% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LAB B Stock
- Ratings Genomma Lab Internacional, S.A.B. de C.V.